ALDX vs. WVE, ANIP, DYN, INDV, AMPH, LQDA, ETNB, EVO, SPRY, and ARDX
Should you be buying Aldeyra Therapeutics stock or one of its competitors? The main competitors of Aldeyra Therapeutics include Wave Life Sciences (WVE), ANI Pharmaceuticals (ANIP), Dyne Therapeutics (DYN), Indivior (INDV), Amphastar Pharmaceuticals (AMPH), Liquidia (LQDA), 89bio (ETNB), Evotec (EVO), ARS Pharmaceuticals (SPRY), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical preparations" industry.
Aldeyra Therapeutics vs.
Aldeyra Therapeutics (NASDAQ:ALDX) and Wave Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, community ranking, institutional ownership, valuation, dividends and profitability.
Aldeyra Therapeutics has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -0.93, suggesting that its share price is 193% less volatile than the S&P 500.
Aldeyra Therapeutics received 118 more outperform votes than Wave Life Sciences when rated by MarketBeat users. Likewise, 69.44% of users gave Aldeyra Therapeutics an outperform vote while only 67.78% of users gave Wave Life Sciences an outperform vote.
Aldeyra Therapeutics has a net margin of 0.00% compared to Wave Life Sciences' net margin of -66.50%. Aldeyra Therapeutics' return on equity of -43.01% beat Wave Life Sciences' return on equity.
59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of Wave Life Sciences shares are owned by institutional investors. 8.5% of Aldeyra Therapeutics shares are owned by insiders. Comparatively, 29.1% of Wave Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Aldeyra Therapeutics had 11 more articles in the media than Wave Life Sciences. MarketBeat recorded 21 mentions for Aldeyra Therapeutics and 10 mentions for Wave Life Sciences. Wave Life Sciences' average media sentiment score of 0.91 beat Aldeyra Therapeutics' score of -0.14 indicating that Wave Life Sciences is being referred to more favorably in the news media.
Aldeyra Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 447.95%. Wave Life Sciences has a consensus target price of $22.60, indicating a potential upside of 258.39%. Given Aldeyra Therapeutics' higher possible upside, research analysts plainly believe Aldeyra Therapeutics is more favorable than Wave Life Sciences.
Aldeyra Therapeutics has higher earnings, but lower revenue than Wave Life Sciences.
Summary
Aldeyra Therapeutics beats Wave Life Sciences on 9 of the 15 factors compared between the two stocks.
Get Aldeyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aldeyra Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ALDX) was last updated on 4/4/2025 by MarketBeat.com Staff
Buy ALDX Stock Free ALDX Stock Alerts